巨细胞病毒疫苗,埃博拉病毒 z-bo 2020-10-21 321

　　In addition to proving that the cytomegalovirus vaccine has an anti-Ebola virus effect, the researchers also studied its protective mechanism. Theoretically, the herpes virus vaccine can produce target proteins (such as Ebola virus glycoprotein) at different times after vaccination. Currently, cytomegalovirus vaccines produce Ebola virus glycoproteins in the later stages of vaccination. The results of producing large amounts of Ebola virus antibodies without detecting Ebola-specific T cells are surprising. The immune transformation of this antibody has not been seen in the primate spore virus vaccine. The spore virus vaccine usually reacts with a large number of T cells, but almost no response to antibodies. Dr. Michael Jarvis, who is in charge of the project at Plymouth University, said: "This is a completely unexpected finding." "This study requires further investigation, but the results of the study indicate that it may be based on The immune function of antibodies against the target antigen or T cells. This is the Ebola virus. What is exciting is not because the devastating effects of Ebola virus on the number of wild apes in Africa are unknown.

　　The current research uses direct vaccination, but the giant virus vaccine at this location can be transmitted between animals. This may be a way to protect this inaccessible animal population. The current research is an improvement. The pull virus vaccine was brought to humans. Not only is it intended to be applied, but it is also intended to be used in humans after this "self-spreading vaccine" is applied to Sabola virus and other wild animals.